Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Life Sciences Partners

Investor type Private Equity Firm
Founders Clemens Van Blitterswijk Frits Van Der Have Rudy Dekeyser

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 146
Average round size
info
The average size of a deal this fund participated in
$31M
Portfolio companies 92
Rounds per year 6.08
Lead investments 44
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.37
Exits 43
Key employees 11

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Medical Device
Summary

The venture was found in Europe in The Netherlands. The main office of represented VC is situated in the Amsterdam.

The fund was created by Clemens Van Blitterswijk, Rudy Dekeyser. The overall number of key employees were 10.

Opposing the other organizations, this Life Sciences Partners works on 4 percentage points more the average amount of lead investments. The top activity for fund was in 2007. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2014.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Life Sciences Partners, startups are often financed by Kurma Partners, Idinvest Partners, VI Partners AG. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Idinvest Partners, Johnson & Johnson Development Corporation. In the next rounds fund is usually obtained by Novartis Venture Fund, LSP BioVentures, Gimv.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Therapeutics, Biopharma. Among the various public portfolio startups of the fund, we may underline Santarus, Hyperion Therapeutics, Merus Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Life Sciences Partners:
Typical Co-investors
Life Sciences Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Life Sciences Partners:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ImCheck Therapeutics

Biopharma
Biotechnology
Health Care
Life Science
Therapeutics
$113M13 Jun 2022 Marseille, Provence-Alpes-Côte d'Azur, France

Ariceum Therapeutics

Health Care
Medical
Therapeutics
$29M08 Jun 2022 Berlin, Berlin, Germany

Perfuze

Biotechnology
Health Care
Medical
Medical Device
$26M09 Feb 2022 Galway City, County Galway, Ireland

ViCentra

Health Care
Medical
Medical Device
$76M16 Dec 2021 Utrecht, Utrecht, Netherlands

AviadoBio

$80M02 Dec 2021 London, England, United Kingdom

HotSpot Therapeutics

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
Therapeutics
$100M29 Nov 2021 Cambridge, Massachusetts, United States

DNA Script

Biotechnology
Health Care
Life Science
Medical
$165M26 Oct 2021 France, Ile-de-France, France

Egle Therapeutics

Biotechnology
Health Care
Therapeutics
$47M22 Oct 2021 Paris, Ile-de-France, France

OneProjects

Health Care
Medical Device
$8M14 Oct 2021 Dublin, County Dublin, Ireland

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Life Sciences Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: